Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune checkpoint inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which acts both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Follow-Up Questions
Who is the CEO of Briacell Therapeutics Corp?
Dr. William Williams is the President of Briacell Therapeutics Corp, joining the firm since 2016.
What is the price performance of BCTX stock?
The current price of BCTX is $9.14, it has increased 0.66% in the last trading day.
What are the primary business themes or industries for Briacell Therapeutics Corp?
Briacell Therapeutics Corp belongs to Biotechnology industry and the sector is Health Care
What is Briacell Therapeutics Corp market cap?
Briacell Therapeutics Corp's current market cap is $17.1M
Is Briacell Therapeutics Corp a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Briacell Therapeutics Corp, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
